Product Overview

n

Lipvas 10 mg is a prescription tablet that contains atorvastatin, a potent lipid‑lowering agent manufactured by Cipla Limited. It is classified under the therapeutic category of cardiovascular health, specifically indicated for the management of elevated low‑density lipoprotein (LDL) cholesterol in adults. The product is supplied in a strip containing ten film‑coated tablets, each delivering a precise 10 mg dose of the active ingredient. Packaged in sizes of 60, 90, or 120 tablets, Lipvas offers flexibility for patients requiring long‑term cholesterol control. Delivery typically occurs within six to fifteen days, depending on the shipping destination. This medication is intended for oral use and should be stored at room temperature, away from moisture and direct sunlight.

n

What is Lipvas 10 mg (Atorvastatin)

n

Atorvastatin belongs to the class of HMG‑CoA reductase inhibitors, commonly referred to as statins. It functions by blocking the enzyme responsible for cholesterol synthesis in the liver, thereby reducing circulating LDL cholesterol by up to 50 % and modestly increasing high‑density lipoprotein (HDL) cholesterol. In addition, atorvastatin lowers triglyceride levels and exerts a stabilizing effect on atherosclerotic plaques. Lipvas 10 mg provides a standardized dose that is suitable for initiation of therapy in patients with primary hypercholesterolemia or mixed dyslipidemia. The tablet formulation is film‑coated to improve gastrointestinal tolerance and to ensure consistent dissolution in the gastrointestinal tract.

n

Uses and Benefits

n

The primary clinical use of Lipvas 10 mg is the reduction of elevated LDL cholesterol, which lowers the risk of myocardial infarction, ischemic stroke, and revascularization procedures in patients with established cardiovascular disease or multiple risk factors. Regular use of atorvastatin has been shown in large outcome trials to improve overall survival in high‑risk populations. Beyond lipid modulation, the drug contributes to anti‑inflammatory effects within the vascular wall, stabilizing plaques and reducing endothelial dysfunction. Patients often experience a measurable improvement in blood lipid profiles within four to six weeks of consistent dosing, supporting its role as a first‑line agent in comprehensive cardiovascular risk management.

n

How It Works

n

The mechanism of action of atorvastatin involves inhibition of HMG‑CoA reductase, the rate‑limiting enzyme in the mevalonate pathway that produces cholesterol precursors. By decreasing the availability of these precursors, the liver up‑regulates LDL receptors on its surface, enhancing the clearance of LDL particles from the bloodstream. This dual effect—reduced production and increased removal—leads to a net decline in circulating cholesterol. Additionally, atorvastatin modestly influences the synthesis of inflammatory cytokines and improves endothelial nitric oxide production, contributing to vascular health beyond lipid lowering. The drug’s pharmacokinetics are characterized by oral bioavailability of approximately 30 % and extensive hepatic metabolism via the cytochrome P450 3A4 pathway.

n

Dosage Guidelines

n

The recommended starting dose of Lipvas 10 mg is one tablet taken orally once daily, preferably in the evening, as cholesterol synthesis peaks during nighttime hours. The tablet should be swallowed whole with a full glass of water and may be taken with or without food; however, consistency in timing enhances therapeutic efficacy. If the patient’s LDL cholesterol remains above target after four weeks, the physician may increase the dose to 20 mg, and subsequently to 40 mg or 80 mg based on therapeutic response and tolerance. Dose adjustments are also necessary for patients with hepatic impairment, elderly individuals, or those concurrently using certain CYP3A4‑inhibiting medications. Adherence to the prescribed regimen is essential to achieve optimal lipid control.

n

Side Effects

n

Like all pharmaceutical agents, Lipvas 10 mg may be associated with adverse effects, although most are mild and transient. The most frequently reported side effects include myalgia, fatigue, and gastrointestinal discomfort such as nausea or constipation. Rare but serious complications can involve elevated liver enzymes, myopathy, or rhabdomyolysis, particularly when high doses are combined with renal dysfunction or excessive alcohol consumption. Patients should be advised to report unexplained muscle pain, dark urine, or persistent jaundice promptly. Additionally, some individuals may experience skin rash or headache. Regular monitoring of liver function tests is recommended at baseline and periodically during treatment, especially when co‑existing hepatic conditions are present.

n

Warnings and Precautions

n

Lipvas 10 mg is contraindicated in pregnant or lactating women, as well as in patients with active liver disease or those who have experienced an hypersensitivity reaction to atorvastatin or any component of the formulation. Concurrent use with certain macrolide antibiotics, antifungal agents, or protease inhibitors can increase plasma concentrations of the drug, raising the risk of toxicity; therefore, a dose adjustment or alternative therapy may be required. Patients should avoid excessive intake of grapefruit juice, which can potentiate the effect of CYP3A4 inhibition. Caution is also advised in individuals with renal impairment, hypothyroidism, or those undergoing surgery, as these conditions may alter drug metabolism. Always consult a healthcare professional before initiating or modifying therapy.

n

Frequently Asked Questions

n

n
1. Lipvas 10 mg contains atorvastatin, which is prescribed to lower high cholesterol levels and reduce the risk of heart attack, stroke, and other cardiovascular events. It works by inhibiting the enzyme that produces cholesterol in the liver, thereby decreasing LDL and triglyceride concentrations in the bloodstream. This medication is part of a broader treatment plan that includes diet, exercise, and sometimes other lipid‑lowering drugs. For detailed clinical guidance, see the FDA prescribing information.

n

2. Most patients experience a measurable decline in LDL cholesterol after four to six weeks of consistent daily dosing, although the full therapeutic effect may take up to twelve weeks. Triglyceride levels typically begin to drop within the same timeframe, while HDL cholesterol may rise modestly after several months. Ongoing monitoring by a healthcare provider is essential to assess progress and adjust the dose if needed. For evidence‑based data on lipid‑lowering timelines, refer to the NIH cholesterol management guidelines.

n

3. Lipvas can be used alongside many common medications, but interactions must be considered. Certain drugs such as cyclosporine, some antibiotics, and antifungal agents may increase atorvastatin blood levels, raising the risk of muscle toxicity. It is important to inform your physician about all prescription, over‑the‑counter, and herbal products you are taking. The Drugs.com interaction checker provides a comprehensive overview of potential drug interactions.

n

4. If you forget to take a scheduled dose of Lipvas, take it as soon as you remember unless it is close to the time of your next dose. In that case, skip the missed tablet and resume your regular dosing schedule; do not double up to compensate. Consistency helps maintain steady drug levels and maximizes cholesterol‑lowering benefit. For more detailed dosing recommendations, consult the MedlinePlus dosing information.

n

5. While taking Lipvas, it is advisable to follow a heart‑healthy diet low in saturated fats and trans‑fatty acids, and to limit alcohol intake. Grapefruit juice should be avoided because it can increase atorvastatin concentrations and the risk of side effects. Regular physical activity further enhances lipid control. For personalized dietary advice, discuss with your healthcare provider or a registered dietitian. Learn more about diet and cholesterol at the MedlinePlus nutrition page.

n

Related Products

• Ciplox 750mg (Ciprofloxacin)
• Diclofenac SR 100 mg
• Reactin 50 mg (Diclofenac)
• Cromal Forte Eye Drop (Sodium Cromoglycate)
• Alendronic Acid 35 mg (Generic)
• Rizact 5 mg (Rizatriptan)
• Flunarizine 5 mg (Generic)
• Warf 1 mg (Warfarin)
• Warf 2 mg (Warfarin)
• Warf 3 mg (Warfarin)
• Mucinac 200 mg (Acetylcysteine)
• Temozolomide 20 mg (Generic)